FDA approves new treatment to reduce the risk of breast cancer returning

July 17, 2017 – The U.S. Food and Drug Administration today approved neratinib for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, Neratinib is the first extended adjuvant therapy, a form of therapy that is taken after an initial treatment to further lower the risk of the cancer coming back. Neratinib is indicated for adult patients who have been previously treated with a regimen that includes the … (leggi tutto)